With the development of methods to solubilize and to analyze the amino acid sequences of various amyloids, an exciting new field has opened up. It has been learned that amyloid is a generic term, defined by Congo red positivity and characterized by fibrillar proteins with a beta-pleated sheet configuration (1) . Typically, a serum protein subunit of low molecular weight is polymerized into unbranched fibrils, which accumulate and destroy normal tissue by unclear mechanisms. The most common examples are AL amyloidosis seen in plasma cell neoplasms, with a monoclonal light chain as the subunit, and AA amyloidosis where serum protein SAA is the subunit in a variety of chronic inflammatory states (1) .
Over the past 5 years a new form of amyloidosis has been recognized with increasing frequency in long-term hemodialysis patients. We and others have demonstrated that the protein subunit of this amyloid is /32 microglobulin (/32m), hence the designation A/32m (2) (3) (4) . The clinical presentation of A/32m amyloidosis includes asymptomatic lytic bone lesions, carpal tunnel syndrome, tenosynovitis, destructive arthropathies of the wrist and long bones, and pathologic fractures (5-8). Considerable morbidity results in these individuals who have usually been receiving regular hemodialysis for more than 5 years. Both of our initial patients required bilateral hip replacement surgery (6), and one has had a spontaneous pelvic fracture. A/32m amyloidosis has not had significant effects on other organs, unlike AA or AL amyloidosis, although it has been found in' rectum (9, 10) and one coronary artery (11) . A recent autopsy study of 7 patients, who had undergone hemodialysis for 9-18 years and who did not have AA or AL amyloidosis, was unable to detect A/32m in any extraskeletal viscera despite numerous tissues examined, except in small vascular deposits in a single patient (12) . Not surprisingly, skin biopsies and fat aspirates have been negative for A/32m in our experience and that of others (8) (9) (10) (11) (12) . Much about this illness remains to be defined, including its prevalence, pathogenesis, and treatment.
The International Journal Of Artificial Organs / Vol. 10/ n. 5, 1987/ pp. [281] [282] [283] Although /32m has been around in the medical literature for 20 years, it has served mainly as a curiosity. /32m has 99 amino acid residues, a molecular weight of 11,818 daltons, and a prominent beta-pleated sheet configuration. /32m circulates in only one allelic form in man, being derived mainly from class I histocompatibility antigens on the surface of nucleated cells (2) (3) (4) . It is freely filtered at the glomerulus, partially reabsorbed and degraded by renal tubular cells, and excreted in the urine (13) . Increased urinary excretion is a sensitive indicator of tubular damage, such as in heavy metal intoxications. Serum /32m concentrations are elevated in rheumatic diseases, organ transplant rejection, hematopoietic neoplasia, the acquired immunodeficiency syndrome, and renal failure (13) (14) . Unfortunately, in renal failure the degree of elevation of the serum /32m level does not correlate with duration of hemodialysis or distinguish patients with A/32m amyloidosis from unaffected chronic dialysis patients (15) (16) (17) .
The pathogenesis of A/32m amyloidosis and its predilection for the skeletal system remain undefined. In contrast to AL or AA amyloidosis, the intact, unmodified /32m molecule is polymerized into the amyloid protein (4). The fibrils are curved unlike those of AL or AA amyloid (11) . Undoubtedly, at least two factors are critical to the pathogenesis of A/32m. First, very high circulating levels of the subunit protein, /32m, exist in all renal failure patients. Second, /32m is predictably amyloidogenic, since it has a beta-pleated sheet tertiary structure (4). Yet a minority of long-term dialysis patients develop this illness. Our own survey indicates that 20-30% of those on hemodialysis for over 5 years will develop lytic bone lesions and/or carpal tunnel syndrome due to A/32m. More serious complications occur in about one third of this group. The involvement of the skeletal system and sparing of the vasculature suggest a specific factor present in bone or joint tissues that may trigger /32m polymerization. Both of our index cases had dialysis dementia, presumably from aluminum intoxication (6). Aluminum may be this amyloidogenic factor (4).
Once A/32m amyloidosis has developed, the success of therapy is directly related to the extent of disease. Carpal tunnel syndrome responds dramatically to surgical release if diagnosed promptly. We believe that skeletal radiologic surveys, particularly of the pelvis and long bones, should be conducted yearly on long-term dialysis patients, so that enlarging lytic lesions may be detected before fractures occur. Prophylactic fixation of these lesions of weight-bearing bones may prevent fractures. If hip fractures do occur, we prefer total joint replacement to nailing, since nail migration has been a problem. Intensive physical therapy is also recommended to prevent loss of mobility, particularly of shoulder joints.
It is entirely speculative whether adoption of or change to another available dialysis modality will prevent or improve Af32m amyloidosis. However, it is clear that patients who hemodialyze against cellulosic membranes have higher serum 132m levels than do patients who hemodialyze versus polyacrylonitrile or polysulfone membranes (18, 19) . Preliminary evidence points to a lower incidence of Af32m amyloidosis in the latter patient groups (19, 20) . Chronic peritoneal dialysis (CPO) has been shown to clear 132m (17) (18) (19) (20) (21) and CPO patients had lower serum levels of 132m than hemodialysis patients in one series (21), but were not significantly different in another (17) . However, CPO has been in general use for only about 10 years and fewer patients dialyze in this manner. It is not known if CPO prevents Af32m, since a CPO patient has recently been reported to have developed Af32m amyloidosis (17) . High flux polysulfone hemodialyzers have been shown to decrease patient serum 132m levels by 30-50% within one month of switching from cuprophan membranes, but serum levels are still 5-10 times normal (unpublished observations). Renal transplantation has not yet been reported to be effective in re-versing Af32m amyloidosis. Possibly, Af32m amyloid is inert and cannot be degraded by physiologic mechanisms, even if serum 132m levels are decreased. Thus, no therapy directed at the amyloid itself has yet been proven effective.
In conclusion, a new amyloidosis, Af32m, has been discovered in chronic dialysis patients. The amyloid protein is composed of polymeric, intact 132m. Clinical illness is a result of deposition of Af32m in bones and joints. Af32m can be diagnosed reliably by a combination of immunochemical techniques and electron microscopy (11) , and is easily separable from other systemic amyloidoses. Certain aspects of Af32m amyloidosis are treatable, especially carpal tunnel syndrome, but much remains to be learned about its pathogenesis, prevention and definitive treatment. Af32m amyloidosis deserves the special attention not only of nephrologists, but also of pathologists, radiologists, rheumatologists and orthopedic surgeons. 
